Researchers at the University of Toronto, University Health Network and SickKids have developed a promising new approach that could eventually help treat thousands of genetic disorders. Because nonsense mutations can also occur in genes involved in muscular diseases, this emerging tRNA technology could potentially become relevant to conditions such as Duchenne muscular dystrophy (DMD) in the future, although it has not yet been tested as a treatment for DMD.
The research focuses on transfer RNA (tRNA), a molecule involved in the process cells use to produce proteins. By engineering tRNA, scientists aim to overcome one of the most difficult types of genetic mutations: nonsense mutations.
The study, published in Science on August 27, demonstrates in laboratory and preclinical models that engineered tRNA can restore the production of full-length, functional proteins affected by nonsense mutations.
Table of Contents
What Are Nonsense Mutations?
Genes contain instructions that cells use to produce proteins. These instructions are read in three-letter units called codons. Most codons tell the cell which amino acid to add to a growing protein, while three codons act as signals telling the cell to stop.
A nonsense mutation occurs when a genetic change creates a stop signal too early.
This is like placing a stop sign in the middle of a road. The cell stops producing the protein before it is finished. As a result, the protein may be shortened and non-functional, or very little full-length protein may be produced.
Although nonsense mutations account for an estimated 11 percent of inherited genetic disorders, they affect thousands of patients across many different diseases, including some forms of cystic fibrosis and muscular and neurological disorders.
Why Is tRNA Research Important for Genetic Disorders?
One of the major challenges in genetic medicine is the enormous number of disease-causing mutations. Creating a separate treatment for every individual mutation can be extremely difficult, particularly when a mutation affects only a small number of patients.
This is where tRNA research for nonsense mutations could offer a different strategy.
Importantly, nonsense mutations may occur in many different genes, but they result in only three possible premature stop codons. This creates the possibility of developing a therapeutic approach that targets the type of mutation rather than a specific gene.
Researchers therefore envision a potential “one-size-fits-many” strategy, in which one engineered tRNA could potentially address the same premature stop signal across multiple genes and diseases.
How Does Engineered tRNA Work?
The researchers designed tRNA molecules that can recognize a premature stop signal and insert the appropriate amino acid instead.
This allows the cell to continue reading the genetic instructions and potentially produce a full-length protein.
The resulting protein may not always be completely identical to the natural protein. However, if enough functional activity is restored, this could be significantly better than producing little or no functional protein.
In simple terms, instead of changing the DNA itself, the researchers are attempting to bypass the premature stop signal during protein production.
Making tRNA Stronger and More Effective
Developing tRNA into a practical medicine has not been straightforward. One important challenge is making engineered tRNA active and stable enough to produce meaningful amounts of protein.
The research team found that adding a specific chemical modification naturally found in tRNA made the engineered molecule more active and longer-lasting.
This was an important step because a therapeutic tRNA needs to remain functional long enough to have a meaningful biological effect.
Delivering tRNA to the Right Cells
Another major challenge is delivery.
Even a highly effective tRNA cannot work as a medicine if it cannot reach the cells that need it. Researchers therefore developed specialized lipid nanoparticles (LNPs) to deliver tRNA.
Although lipid nanoparticles have previously been used to deliver mRNA, the researchers redesigned them specifically for tRNA. They screened approximately 1,000 different lipids to identify a suitable delivery system.
This combination of engineered tRNA and specialized delivery technology is one of the key advances of the study.
tRNA Restores Protein Production in Cystic Fibrosis Models
The researchers initially tested the approach in cystic fibrosis models involving nonsense mutations in the CFTR gene.
Existing CFTR modulator treatments, including Trikafta, have transformed treatment for many people with cystic fibrosis. However, these medicines are not effective for patients whose disease results from certain nonsense mutations because the necessary full-length CFTR protein may never be produced.
In human airway cells carrying two common nonsense mutations, engineered tRNA restored production of the CFTR protein and the protein was functional. The restored protein also remained detectable for more than 40 days.
Potential for Combination Therapy
The researchers also tested cells from a cystic fibrosis patient with a complex CFTR genotype containing four mutations, including two nonsense mutations.
In these patient-derived organoids, neither tRNA nor Trikafta alone produced a strong response. However, when used together, the combination restored full-length CFTR production and allowed Trikafta to act on the newly produced protein.
This suggests that tRNA therapies might potentially be combined with existing treatments rather than replacing them.
Could tRNA Research Treat Other Genetic Diseases?
The most important potential of this research extends beyond cystic fibrosis.
Because the same three premature stop codons can appear in many different genes, an engineered tRNA designed to recognize one of these signals could potentially be adapted for multiple genetic diseases.
Researchers are now exploring how the platform could be applied to other organs and tissues. Each target tissue may require its own specialized delivery system.
For lung diseases, the team has already shown that its lipid nanoparticles can survive conversion into a fine mist, raising the possibility of future inhaled tRNA treatments.
A Promising but Early-Stage Approach
tRNA research for nonsense mutations is still at the preclinical stage, and much more research is required before this technology can become an approved treatment for patients.
Nevertheless, the concept is significant. Rather than developing a completely different therapy for every disease-causing mutation, researchers are exploring whether a common tRNA-based platform could target the underlying type of mutation across multiple genes.
If successful, tRNA therapeutics could eventually become a new platform for treating genetic disorders caused by nonsense mutations, including diseases that currently have few or no effective treatment options.
Discover More: Explore Duchenne Clinical Trials
